[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"musculoskeletal-abnormalities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:musculoskeletal-abnormalities":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,82,112,142,166,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100641879","comparing-two-soft-tissues-technique-on-piriformis-syndrome-patients-100641879",false,"NCT07661485","Comparing Two Soft Tissues Technique on Piriformis Syndrome Patients","Effect of Myofascial Release as Compared to Post Isometric Relaxation in Improving Pain and Lower Extremity Function in Piriformis Syndrome","MPR-PIR","Inclusion Criteria:\n\n* Positive Lasegue sign\n* Positive FAIR test\n* Grade 1-3 tenderness on palpation of piriformis between sacrum and greater trochanter of femur\n* 4 or more pain intensity on the VAS scale\n\nExclusion Criteria:\n\n* Lower extremity injuries including ligament, tendon injuries, muscle strains as well as nerve injuries\n\n  * Systemic diseases including tuberculosis, multiple sclerosis, Parkinson's disease as well as chronic inflammatory conditions\n  * Congenital deformities including hip dysplasia, limb length discrepancy, scoliosis and congenital pelvic asymmetry\n  * Cognitive issues including dementia, severe depression and severe psychotic disorders\n  * Lumbar Radiculopathy\n  * SIJ Dysfunction\n  * Lower Extremity Fractures\n  * Pregnancy\n  * Malignancy","ALL","20 Years","50 Years",{"count":21,"type":22},26,"ESTIMATED","INTERVENTIONAL",[25],"NA","Piriformis Syndrome is a neuromuscular condition with symptoms of pain, numbness and tingling tracing the route of the sciatic nerve, due to the nerve impingement by the piriformis muscle. Two common manual therapy techniques used to treat musculoskeletal conditions are myofascial release and post-isometric relaxation. The intent of the research is to evaluate the effects of myofascial release (MFR) as compared to post-isometric relaxation (PIR) in improving pain and lower extremity function in piriformis syndrome (LEFS). The study population involved 32 individuals aged between 20 to 50 years who will be randomly assigned to two groups; a group that received MFR and a group that received PIR. Both groups received the baseline treatment for four weeks. The Visual Analog Scale (VAS) will be employed to gauge the amount of pain, while the LEFS was used to measure functional mobility",[28,29,30],"Piriformis Syndrome","Musculoskeletal Abnormalities","Sciatica",[32,33,34,35,36],"myofasical release","Post isometric relaxation","physiotherapy","Radiculopathy","Piriformis syndrome","NOT_YET_RECRUITING","2026-06-25",{"date":40,"type":41},"2026-06-30","ACTUAL",{"date":40,"type":22},{"date":44,"type":22},"2026-09-30",{"name":46,"class":47},"University of Faisalabad","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":48},"100604838","phase-4-glp-1r-actions-on-muscle-and-the-skeleton-100604838","NCT07154719","GLP-1R Actions on Muscle and the Skeleton","GRAMS","Inclusion Criteria:\n\n* Subjects will have a BMI between 30kg\u002Fm2\n\n  * 40kg\u002Fm2 (inclusive)\n* Be between 18 and 50 years of age (inclusive).\n* Non-Hispanic Black males and females will be enrolled at PBRC.\n* Rural males and females will be enrolled at MaineHealth.\n* Female subjects will be premenopausal.\n* Females have had their last menstrual period less than 60 days before screening.\n* Females have the absence of menopausal-associated vasomotor symptoms.\n* All subjects must be able to use Lifestyle Toolkit as prescribed for intervention arm.\n\nExclusion Criteria:\n\n\\- Males and females over the age of 50 years of age\n\n* Menopausal females.\n* Subjects on systemic corticosteroids or other agents known to increase loss of muscle and bone mass.\n* Subjects who are on medications that increase or decrease weight status.\n* Subjects having contraindications to tirzepatide in the package insert.\n* Subjects with a history of malignancy other than non-melanoma skin cancer\n* Subjects with known osteoporosis or are on osteoporosis therapies (gonadal hormones or hormone antagonists).\n* Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results.\n* Subjects with a clinically significant hematologic abnormality, kidney disease, liver disease, or diabetes.\n* Females of childbearing potential who do not agree to using an effective method of contraception during the study. Medically acceptable methods include oral contraceptive medication, an intrauterine device (IUD), an implantable contraceptive (such as Implanon), or a barrier method (such as condom or diaphragm with spermicide).\n\nInjectable contraceptives such as Depo-Provera are a cause for exclusion in that they can cause bone loss.\n\nAbstinence is acceptable, as is sexual activity exclusively with same sex partners.\n\nFertility Appreciation Based Methods (natural family planning) are also acceptable forms of addressing childbearing potential in all subjects. A urine pregnancy test (UPT) will be performed on all females of childbearing potential at the screening visit, 3 and 6 months.\n\n* Unable to follow Lifestyle Toolkit as prescribed for intervention arm.\n* Patient Health Questionnaire-9 (PHQ-9) Score equal to or greater than 15 (clinical depression).\n* Adults who are unable to consent.\n* Individuals who are not yet adults (infants, children and teenagers).\n* Pregnant females.\n* Incarcerated individuals.\n* Contraindication to MRI - including but not limited to non-removable metallic or electronic implants, claustrophobia or other fear of confinement, inability to tolerate loud scanner noise, body weight greater than 500 pounds.\n* Subjects with a baseline level of 25-OH vitamin D \\\u003C15 ng\u002Fml will be excluded from the trial. The subject's physician will be notified, and the subject will be referred to their primary care physician.\n* Any significant EKG abnormalities that are considered a risk for utilizing weight management therapies.","18 Years",{"count":58,"type":22},50,[60],"PHASE4","The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.",[29,63,64,65,66],"Obesity","Sarcopenic Obesity","Osteoporosis","Drug Effect",[68,69,70,71],"GLP-1 agonists","Obesity treatments","Muscleskeletal loss","Tirzepatide","RECRUITING","2026-05-26",{"date":75,"type":41},"2026-05-29",{"date":77,"type":41},"2025-10-09",{"date":79,"type":22},"2027-05-01",{"name":81,"class":47},"Pennington Biomedical Research Center",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":5},"100545332","advanced-surgical-simulation-processes-in-the-correction-of-skeletal-defects-and-deformities-100545332","NCT06380530","Advanced Surgical Simulation Processes in the Correction of Skeletal Defects and Deformities","SIMULA","Inclusion Criteria:\n\n* Diagnosis of musculoskeletal disease (MSD) of the limbs;\n* Need for mono- or polyaxial correction by one or more osteotomies;\n* Presence of specific consent to participate in the trial;\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the study\n* Patients who do not undergo radiological follow-up examinations for VSP or for whom the radiological record is insufficient to conduct VSP;\n* Patients who undergo different interventions for correction of MSD (growth modulation interventions by epiphysiodesis and hemiepiphysiodesis, progressive correction by external circular\u002Fhexapodal fixation);\n* Pregnant or lactating women","2 Years","40 Years",{"count":92,"type":22},100,[25],"Virtual Surgical Planning (VSP), Computer-Aided Surgical Simulation (CASS) for bone corrections, and the customization of implants and devices through 3D printing, known as Patient-Specific Instruments (PSI) and Graft-Specific Instruments (GSI), are assuming increasingly central roles in orthopedic clinical and surgical practice.\n\nOne area witnessing notable advancement is the treatment of musculoskeletal disorders (MMS) in children, adolescents, and young adults. These disorders involve severe and rare abnormalities in skeletal formation and development across three-dimensional planes, often affecting multiple limbs. Managing such deformities is complex, challenging to standardize, and prone to unpredictable clinical, radiographic, and functional outcomes.\n\nThe application of 3D modeling and printing technologies offers a deeper understanding of deformities and facilitates improved prediction, precision, reproducibility, and safety in surgical interventions.\n\nThe Musculoskeletal Apparatus Network (RAMS Network) centers are equipped with advanced 3D laboratories for surgical simulation and planning, aligned with the overarching goal of improving surgery quality through \"in-silico\" medicine (ISM) principles.\n\nAt present, numerous complex surgeries involving Virtual Surgical Planning (VSP) and sterilizable 3D-printed Patient-Specific Instruments (PSI) and\u002For Graft-Specific Instruments (GSI) are being simulated and performed at the Rizzoli Institute. Preliminary data from previous protocols indicate a significant reduction in surgical time with the implementation of VSP and the utilization of PSI and GSI.\n\nThe aim of this study is to enhance the current process of simulating, planning, and designing surgical support tools within 3D Printing Point-of-Care (3D POC) facilities. To achieve this, it is imperative to expand case volumes and systematically organize, categorize, and standardize simulation and planning procedures.",[96,29,97],"Musculoskeletal Deformity","Musculoskeletal Disorder",[99,100,101,102],"Virtual Surgical Planning","Patient-Specific instrument","Graft-Specific instrument","Pediatric Orthopedics","2025-12-19",{"date":105,"type":41},"2025-12-26",{"date":107,"type":41},"2024-10-31",{"date":109,"type":22},"2029-05",{"name":111,"class":47},"Istituto Ortopedico Rizzoli",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":119,"minAge":120,"maxAge":56,"enrollmentInfo":121,"targetDuration":123,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":48},"100607558","effects-of-emicizumab-treatment-in-patients-with-hemophilia-a-100607558","NCT07190118","Effects of Emicizumab Treatment in Patients With Hemophilia A","Effects of Emicizumab Treatment on the Musculoskeletal System in Children With Hemophilia A: A Prospective Study","Inclusion Criteria:\n\n* Children who are under 18 years of age,\n* Have been diagnosed with Hemophilia A by a physician,\n* Have a factor level of 1% (IU) or less,\n* Have inhibitors positive or negative,\n* Have no obstacles to starting subcutaneous (emicizumab) treatment,\n* Willing to participate in the study\n\nExclusion Criteria:\n\n\\- Children with a history of cerebrovascular bleeding who present any neurological findings that would prevent participation in the study","MALE","1 Year",{"count":122,"type":22},20,"6 Months","OBSERVATIONAL","The aim of our study is to investigate the effects of emicizumab treatment on the musculoskeletal system in children with hemophilia A.",[127,128,29],"Hemophilia A","Musculoskeletal Assessment",[127,130,131,132],"Emicizumab","Musculoskeletal system","Measurement","2025-09-23",{"date":135,"type":41},"2025-09-24",{"date":137,"type":22},"2025-09-30",{"date":139,"type":22},"2026-02-10",{"name":141,"class":47},"Hasan Kalyoncu University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":152,"studyType":124,"phases":4,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100592648","prospective-evaluation-assessing-u2-mb-total-knee-system-100592648","NCT06996158","Prospective Evaluation Assessing U2 MB™ Total Knee System","Prospective Evaluation Assessing Performance, Survivorship and Patient Reported Outcome Measures of Mobile Bearing Total Knee System (U2 MB™ Knee).","Inclusion Criteria:\n\n1. All patients suitable for a cemented Total Knee Replacement, MBC design\n2. All elective pathology (including Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis not requiring stemmed components, Avascular necrosis)\n3. Willing to voluntarily sign the informed consent form\n4. Willing and able to comply with the protocol, able to read and complete the required forms, and willing and able to adhere to the requirements of the protocol through the 10-year postoperative follow-up visit.\n\nExclusion Criteria:\n\n1. Skeletally immature (less than 21 years of age) at time of implantation\n2. Active native knee joint infection\n3. Post-traumatic arthritis requiring stemmed components\n4. Malignancy around the knee\n5. All patients who are personally unable to take part in fully informed consent (dementia, reduced AMTS etc)\n6. Patients who will not be available to return for the predetermined appointments in order to complete the 10 years follow-up\n7. Has inadequate neuromuscular status (e.g., prior paralysis, fusion, and\u002For inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable\n8. Currently enrolled in another clinical investigation which could affect the endpoints of this protocol","21 Years",{"count":151,"type":22},150,"13 Years","The goal of this study is to evaluate the safety and effectiveness of the United Orthopaedics Mobile Bearing Total Knee System (U2 MB™ Knee) in patients undergoing total knee replacement surgery due to end-stage knee osteoarthritis. The main questions it aims to answer are:\n\n1\\. What is the component survivorship of the U2 MB™ Knee system at 1, 3, 5, and 10 years?\n\nParticipants will:\n\n1. Return for follow-up assessments at Year 1, Year 3, Year 5, and Year 10 after surgery\n2. Undergo clinical evaluations including functional outcome scoring, radiographic imaging.\n\nThis study will take place across three investigational sites and will involve 150 knee replacements using U2 MB™ components. The study's objectives include assessing early to long-term outcomes in terms of implant survivorship, clinical function, patient satisfaction, radiological findings, and overall safety of the device over a 10-year period.",[155,29],"Osteoarthritis","2025-05-21",{"date":158,"type":41},"2025-05-30",{"date":160,"type":22},"2025-05-26",{"date":162,"type":22},"2038-11-30",{"name":164,"class":165},"MSK Doctors & Associates Ltd","INDUSTRY",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100434233","evaluation-of-non-surgical-and-arthroscopic-treatment-for-hip-microinstability-100434233","NCT04934462","Evaluation of Non-Surgical and Arthroscopic Treatment for Hip Microinstability","Prospective Evaluation of Non-Surgical and Arthroscopic Treatment for Hip Microinstability","Inclusion Criteria:\n\n* Hip microinstability\n* Minimum 18 years old\n\nExclusion Criteria:\n\n* Hip osteoarthritis\n* Severe hip dysplasia\n* Perthes disease or avascular necrosis of the femoral head\n* Previous surgery to the hip joint",{"count":21,"type":22},[25],"Microinstability of the hip joint is an important cause of hip pain and reduced hip function in young and active individuals. Hip microinstability is due to extraphysiologic hip motion and could be secondary to acetabular dysplasia, connective tissue disorder, macrotrauma, microtrauma, iatrogenic- and idiopathic causes. Treatment for hip microinstability is initiated with non-surgical treatment consisting of physiotherapy aimed mainly at stability. If non-surgical treatment fails, surgery with arthroscopic plication of the hip joint capsule is the preferred method. This study evaluates non-surgical and arthroscopic treatment for hip microinstability regarding hip function and adverse events.",[29,177],"Hip Injuries",[179,34],"arthroscopy","2025-03-11",{"date":182,"type":41},"2025-03-12",{"date":184,"type":41},"2021-11-26",{"date":186,"type":22},"2026-01",{"name":188,"class":47},"Göteborg University",3,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":197,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":189},"100479596","rct-of-combination-effect-of-vibration-treatment-and-hmb-supplementation-on-myosteatosis-and-nmj-degeneration-100479596","NCT05525039","RCT of Combination Effect of Vibration Treatment and HMB Supplementation on Myosteatosis and NMJ Degeneration","Dissecting the Therapeutic Mechanism of an Effective Combination Treatment Targeting Neuromuscular Junction Dengeneration and Myosteatosis to Combat Sarcopenia","Inclusion Criteria:\n\n* Subjects aged 60 years or above\n* Subjects failed in AWGS algorithm\n\n  1. skeletal muscle mass by BIA (male at \\\u003C7.0 kg\u002Fm\\^2, female at \\\u003C5.7 kg\u002Fm\\^2), and\n  2. handgrip strength (male at \\\u003C28 kg, female at \\\u003C18kg), and\u002For\n  3. gait speed test (\\>1m\u002Fs)\n\nExclusion Criteria:\n\n* Subjects with pathological bone diseases\n* Subjects with chronic inflammatory condition (e.g. rheumatoid arthritis)\n* Subjects with neurological problems\n* Subjects receiving regular exercise\n* Subjecs who are chair-\u002Fbed- bound\n* Subjects with malignancy\n* Subjects with cardiovascular concern such as with pace-maker in-situ\n* Subjects with acute fractures or severe osteoarthritis","60 Years",{"count":199,"type":22},200,[25],"The investigators' pre-clinical study confirms the positive effects of combined treatment (VT + HMB) on reducing fat-to-lean tissue ratio, intramuscular fat infiltration and increasing muscle strength in sarcopenia animal model. The results showed that fat mass could be decreased by \\~32%, while histology Oil Red O staining indicated a decrease of fat by almost 60%; in contrast, lean muscle mass increased by \\~14%. On muscle strength, combined treatment increased twitch force, tetanic force and grip strength by \\~30-66%. These in vivo results are very encouraging and the investigators should explore its potential in clinical translation. As VT and HMB supplement have been commercially available and their compliance rates are satisfactory, they can be translated to clinical application easily. The investigators' next step is to confirm its clinical efficacy, so that sarcopenia becomes a new indication of VT and HMB. The hypothesis is that combined treatment of VT and HMB can retard the progression of sarcopenia in human, in terms of muscle mass, muscle strength and performance.",[203,204,29],"Sarcopenia","Connective Tissue Diseases in Old Age",[203,206,207],"Vibration","Hydroxymethylbutyrate","2025-02-12",{"date":210,"type":41},"2025-02-13",{"date":212,"type":41},"2023-01-12",{"date":214,"type":22},"2025-09",{"name":216,"class":47},"Chinese University of Hong Kong"]